Generic Name and Formulations:
Dalfampridine 10mg; ext-rel tabs.
Indications for AMPYRA:
To improve walking in patients with multiple sclerosis (demonstrated by an increase in walking speed).
Swallow whole. ≥18yrs: max 10mg every 12hrs.
<18yrs: not established.
History of seizures. Moderate to severe renal impairment (CrCl ≤50mL/min). Previous allergies to 4-aminopyridine.
Assess renal function before initiation; monitor at least annually. Mild renal impairment (CrCl 51–80mL/min): increased risk of seizures. Discontinue if signs/symptoms of anaphylaxis occurs. Pregnancy (Cat.C). Labor & delivery. Nursing mothers: not recommended.
Potassium channel blocker.
Discontinue other forms of 4-aminopyridine prior to initiating. Concomitant OCT2 inhibitors (eg, cimetidine) may potentiate the risk of seizures.
UTI, insomnia, dizziness, headache, nausea, asthenia, back pain, balance disorder, MS relapse, paresthesia, nasopharyngitis, constipation, dyspepsia, throat pain; seizures (possible at higher doses), severe allergic reactions.